Emeryville's Adamas Pharmaceuticals Files For $69 Million IPO

Published: Mar 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Adamas Pharmaceuticals, which develops treatments for CNS disorders such as Parkinson's and Alzheimer's, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The Emeryville, CA-based company, which was founded in 2000 and booked $71 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol ADMS.

Help employers find you! Check out all the jobs and post your resume.

Back to news